See more : FUJIFILM Holdings Corporation (FUJIY) Income Statement Analysis – Financial Results
Complete financial analysis of Protect Pharmaceutical Corporation (PRTT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protect Pharmaceutical Corporation, a leading company in the Conglomerates industry within the Industrials sector.
- Bait Vegag Real Estate Development Ltd (BVGG.TA) Income Statement Analysis – Financial Results
- Banque Cantonale de Genève SA (0RMP.L) Income Statement Analysis – Financial Results
- GCP Infrastructure Investments Limited (GCP.L) Income Statement Analysis – Financial Results
- Ningbo Joyson Electronic Corp. (600699.SS) Income Statement Analysis – Financial Results
- Antares Pharma, Inc. (ATRS) Income Statement Analysis – Financial Results
Protect Pharmaceutical Corporation (PRTT)
About Protect Pharmaceutical Corporation
Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties. The company was formerly known as Pro-Tect, Inc. and changed its name to Protect Pharmaceutical Corporation in March 2010. Protect Pharmaceutical Corporation was founded in 1987 and is based in Las Vegas, Nevada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 136.16M | 81.80M | 78.79M | 5.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.85M | 40.22M | 34.43M | 78.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 73.31M | 41.58M | 44.37M | 5.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 53.84% | 50.83% | 56.31% | 98.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.79M | 1.75M | 1.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 123.19K | 1.25M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 115.40K | 41.71K | 30.03K | 30.85K | 23.94K | 554.30K | 0.00 | 392.58K | 2.15K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.38M | 0.00 |
| SG&A | 20.98M | 14.57M | 14.58M | 42.28K | 1.87K | 115.40K | 41.71K | 30.03K | 30.85K | 23.94K | 554.30K | 786.92K | 5.77M | 2.15K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -5.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.77M | 16.32M | 16.49M | 48.11K | 1.87K | 115.40K | 41.71K | 30.03K | 30.85K | 23.94K | 554.30K | 910.11K | 7.03M | 2.15K |
| Cost & Expenses | 88.62M | 56.54M | 50.92M | 126.37K | 1.87K | 115.40K | 41.71K | 30.03K | 30.85K | 23.94K | 554.30K | 910.11K | 7.03M | 2.15K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.38K | 0.00 | 7.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 115.40 | 41.71 | 605.44K | -488.99K | 23.94 | 0.00 | -640.00K | 0.00 | 0.00 |
| EBITDA | 47.54M | 25.26M | 27.88M | 5.81M | -1.87K | -115.40K | -41.71K | 575.41K | -519.84K | -23.94K | -554.30K | -270.11K | -7.03M | -2.15K |
| EBITDA Ratio | 34.92% | 30.88% | 35.38% | 97.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 47.54M | 25.26M | 27.88M | 5.81M | -1.87K | -115.40K | -41.71K | -30.03K | -30.85K | -23.94K | -554.30K | -910.11K | -7.03M | -2.15K |
| Operating Income Ratio | 34.92% | 30.88% | 35.38% | 97.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | -1.37K | -3.00 | -7.21K | 0.00 | -605.44K | 488.99K | 0.00 | 0.00 | 640.00K | 0.00 | 0.00 |
| Income Before Tax | 47.54M | 25.26M | 27.88M | 5.81M | -1.87K | -122.61K | -41.71K | -635.46K | 458.15K | -23.94K | -554.30K | -270.11K | 0.00 | 0.00 |
| Income Before Tax Ratio | 34.92% | 30.88% | 35.38% | 97.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.63M | 2.82M | 7.67M | -206.30K | -171.86K | -115.40 | -38.71 | 0.00 | 0.00 | -23.94 | 0.00 | 0.00 | 7.03M | 2.15K |
| Net Income | 45.91M | 22.44M | 20.21M | 5.81M | -1.87K | -122.61K | -41.71K | -635.46K | 458.15K | -23.94K | -554.30K | -270.11K | -7.03M | -2.15K |
| Net Income Ratio | 33.72% | 27.44% | 25.65% | 97.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.80 | 0.43 | 0.36 | 0.11 | 0.00 | -0.11 | -0.04 | -1.44 | 8.48 | -0.54 | -12.44 | -6.16 | -172.65 | -0.06 |
| EPS Diluted | 0.80 | 0.43 | 0.36 | 0.11 | 0.00 | -0.10 | -0.04 | -1.44 | 8.48 | -0.54 | -12.44 | -6.16 | -172.65 | -0.06 |
| Weighted Avg Shares Out | 57.45M | 52.78M | 56.25M | 54.95M | 54.95M | 1.11M | 1.11M | 442.17K | 54.05K | 44.57K | 44.57K | 43.86K | 40.70K | 33.16K |
| Weighted Avg Shares Out (Dil) | 57.45M | 52.78M | 56.25M | 54.95M | 54.95M | 1.20M | 1.11M | 442.17K | 54.05K | 44.57K | 44.57K | 43.86K | 40.70K | 33.16K |
Protect Pharmaceutical Corp. Announces Appointment Of
Source: https://incomestatements.info
Category: Stock Reports